[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wound-heal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wound-heal":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,45,72,100,130,152,177,206,235,257,292,318,344,363,386,417,441,462,482,505,543,562,589,616,640],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100539890","hyaluronic-acid-and-polynucleotides-for-supra-bony-defects-100539890",false,"NCT06309719","Hyaluronic Acid and Polynucleotides for Supra-bony Defects","Characterizing the Healing of Periodontal Supra-bony Defects Treated With Hyaluronic Acid and Polynucleotides","Inclusion Criteria:\n\n* Systemically healthy males and females ≥18 years old\n* Stage III or IV periodontitis (Papapanou, Sanz et al. 2018)\n* Presence of supra-bony periodontal defects (i.e., defects where the base of the pocket is located coronal to the alveolar crest and characterized by a predominantly horizontal pattern of tissue destruction) confirmed clinically and radiographically at a minimum of two and a maximum of four adjacent teeth and with a probing pocket depth (PPD) \\> 5 mm, following non-surgical periodontal therapy (NSPT). If \\>4 adjacent teeth exhibited the above clinical and radiographic conditions, the four adjacent teeth showing the greatest overall loss of periodontal attachment were included. Wisdom teeth and second molars will not be considered for the study.\n\nIf defect presents with an intrabony component, this should be ≤2 mm.\n\n* Non-surgical periodontal treatment (step 1 and 2) completed within the previous 4 months\n* Full-mouth bleeding score (FMBS) and full-mouth plaque score (FMPS) ≤20%\n\nExclusion Criteria:\n\n* Teeth with degree III mobility\n* Multi-rooted teeth with grade ≥2 furcation involvement\n* Heavy smokers (≥10 cigarettes a day)\n* Untreated caries or endodontic lesions or abscesses on the teeth involved in the surgery\n* Previous periodontal surgery in the area selected for the study\n* History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures (e.g., mitral valve prolapse, artificial heart)\n* Antibiotic or anticoagulant therapy during the month preceding the baseline exam.\n* History of alcohol or drug abuse\n* Medical history that includes uncontrolled diabetes or hepatic or renal diseases, or other serious medical conditions that can have a negative impact on the periodontal condition\n* In treatment with medications that can severely affect bone metabolism and blood clot formation (e.g., anticoagulants, long-term corticosteroids, bisphosphonates, immunosuppressants)\n* Self-reported pregnancy or lactation.","ALL","18 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this pilot study is to describe the early wound healing molecular events and the vascularization pattern associated with the treatment of supra-bony defects with access flap alone or in association with a combined formulation of hyaluronic acid and polydeoxyribonucleotides gel.",[27,28,29,30,31],"Periodontal Diseases","Wound Heal","Periodontal Inflammation","Periodontal Pocket","Periodontal Attachment Loss","RECRUITING","2026-07-01",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2024-10-21",{"date":40,"type":21},"2026-12",{"name":42,"class":43},"Queen Mary University of London","OTHER",2,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100645146","phase-1-amnion-membrane-powder-mohs-study-100645146","NCT07680023","Amnion Membrane Powder Mohs Study","A Phase I Study of Human Amnion Membrane Powder for Enhanced Wound Healing of Mohs Surgery Wound Sites","Inclusion Criteria:\n\n* The subject requires Mohs surgery on the scalp, with the resulting wound extending to the subgalea (all subcutaneous fat removed) and a surface area of at least 4cm2.\n* The subject is willing to complete all follow-up evaluations required by the study protocol.\n* The subject is to abstain from any other covering or treatment of the wound(s) for the duration of the study unless otherwise directed by the study surgeon or their surrogate\n* The subject agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study.\n* The subject and\u002For guardian is\u002Fare able to read and understand instructions and give informed, voluntary, written consent.\n* The subject is able and willing to follow the protocol requirements.\n\nExclusion Criteria:\n\n* The subject's wound site is smaller than 4cm2.\n* The subject's wound site does not extend to the subgalea.\n* The subject has invasive melanoma or high-risk squamous cell carcinoma (defined by poor differentiation, presence of perineural invasion) in which the standard of care is to be referred for adjuvant radiation oncology\n* The subject has a microbiologically proven pre-existing local or systemic bacterial infection.\n* The subject has been receiving a systemic antibiotic for more than 48 hours prior to grafting.\n* Unstable cardiac disorders within the past 6 months including angina, abnormal ECG, history of cardiac arrest, surgery and\u002For other interventional procedure that would preclude the indicated procedure.\n* Hepatic disease or altered liver function as defined by ALT or AST value \\> 3 times the upper limit of normal and\u002For T. Bilirubin \\>1.5 mg\u002FdL at screening.\n* Renal disease or altered renal function as defined by serum creatinine \\> 2 mg\u002FdL at screening, or ESRD.\n* Hemoglobin \\\u003C10.0 or \\>19.0 g\u002FdL\n* Untreated coagulopathy or platelet disorder, or INR \\> 1.6, PTT \\> 38 sec; PLT \\\u003C 50,000 at screening.\n* The subject is known to have a pre-existing, chronic condition that, in the opinion of the Investigator, may interfere with complete re-epithelialization including but not limited to untreated malignancy, uncontrolled diabetes (HbA1c \\>10), autoimmune disease or other immunocompromised diseases, hematological diseases, peripheral artery diseases, and \u002For malnourishment with an albumin \\\u003C 2.5.\n* The subject currently uses illicit substances or has drug or alcohol dependency.\n* The subject is unable to follow the protocol.\n* The subject is taking medication known to have an effect on wound healing or skin pigmentation within 30 days prior to surgery (e.g. corticosteroids, retinoids etc.)\n* The subject has a known hypersensitivity to Compound Sodium Lactate for Irrigation (Hartmann's) solution.\n* The subject is pregnant or lactating or intends to become pregnant during the study.\n* The subject has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives.",{"count":53,"type":21},20,[55],"PHASE1","The purpose of this research study is to test the safety of the amnion membrane powder to see if it improves wound healing in patients undergoing Mohs surgery on the scalp.",[28],[59,60,61],"MOHS surgery","amnion membrane powder","scalp wound healing","NOT_YET_RECRUITING","2026-06-25",{"date":33,"type":36},{"date":66,"type":21},"2026-10",{"date":68,"type":21},"2027-10",{"name":70,"class":43},"Wake Forest University Health Sciences",1,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100542009","phase-3-incisional-negative-pressure-wound-therapy-to-reduce-infection-and-complications-in-high-risk-fractures-100542009","NCT06337292","Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures","Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures: A Multicenter Randomized Controlled Trial","iVAC","Inclusion Criteria:\n\n1. All open or closed tibial plateau or pilon fractures treated operatively with internal fixation at high risk for complication. Any open Gustilo Type I, II or IIIA tibial shaft fracture treated definitively with internal or external fixation with or without ipsilateral leg compartment syndrome if at least one wound is primarily closed.\n2. We define high-risk fractures as those that are either:\n\n   * Closed fracture initially treated with an external fixator (with or without limited internal fixation) and treated definitive more than 3 days later after swelling has resolved;\n   * Any open type I, II or IIIA fracture, regardless of timing of definitive treatment;\n   * Any tibial plateau fracture associated with ipsilateral leg compartment syndrome fasciotomy wounds that has at least one wound primarily closed\n3. Requiring incision for fixation or debridement of 3 cm or greater.\n4. Patients 18 years of age or older\n\nExclusion Criteria:\n\n1. The study injury is already infected at time of study enrollment.\n2. Patient is unable to receive incisional NPWT for any reason.\n3. Patients who have already had definitive fixation prior to enrollment in the study.\n4. Severe problems with maintaining follow-up (e.g., patients who are homeless at the time of injury or those who are intellectually challenged without adequate family support or who are prisoners).\n5. The study injury is a Gustilo Type IIIB or IIIC open fracture.",{"count":81,"type":21},352,[83],"PHASE3","This is a multi-center, pragmatic, parallel arm randomized controlled trial (RCT) of 352 patients with high-risk open or closed tibial plateau fracture, high-risk open or closed tibial pilon fracture, or open tibial shaft fracture with incision \\>3cm. Eligible participants will be randomized to receive either incisional negative pressure wound therapy (NPWT) or a non-suction standard-of-care wound dressing for their definitive wound management. The primary outcome will be a composite outcome to evaluate clinical status 3 months after randomization.",[86,28,87,88,89],"Fracture of Tibia","Infected Wound","Wound Complication","Wound Dehiscence","2026-05-07",{"date":92,"type":36},"2026-05-12",{"date":94,"type":36},"2025-01-01",{"date":96,"type":21},"2028-12-31",{"name":98,"class":43},"Major Extremity Trauma Research Consortium",6,{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100556727","phase-4-coms-for-chronic-ulcers-treatment-100556727","NCT06528873","COMS for Chronic Ulcers Treatment","NAZARÉ: Concurrent Optical and Magnetic Stimulation (COMS) for Treatment of Patients With Chronic Ulcers of Vascular Origin in a Real-world Setting Including Care at Patient's Home, a Prospective Randomized, Controlled, Assessor Blinded, Phase IV, Clinical Trial","NAZARÉ","Inclusion Criteria:\n\nAge ≥ 18 years Clinical diagnosis of venous leg ulcer (VLU) or VLU with peripheral arterial disease (PAD) Ankle-brachial index (ABI) 0.5-1.3 or ankle pressure \\> 60 mmHg Ulcer size 2-50 cm² after debridement at screening Ulcer duration \\> 30 days and \\\u003C 2 years For patients with diabetes: HbA1c ≤ 12% at screening Able and willing to provide written informed consent prior to study procedures\n\nExclusion Criteria:\n\nPregnant or breastfeeding Malignancy in the ulcer area Use of photosensitizing medication within 30 days Severe immunosuppression (including chronic corticosteroid use \\> 10 mg\u002Fday prednisolone equivalent) NYHA class III or IV heart failure End-stage renal disease requiring dialysis Ulcer area reduction \\> 30% during run-in phase Active infection requiring systemic antibiotics at baseline Use of advanced wound therapies (e.g., negative pressure wound therapy, skin substitutes, hyperbaric oxygen) within 2 weeks prior to screening Participation in another interventional clinical trial within 30 days",{"count":109,"type":21},122,[111],"PHASE4","Chronic leg and foot ulcers are defined as wounds that fail to heal in a timely manner, typically persisting for over 4 to 8 weeks without substantial healing despite standard care. These ulcers often result from macro- and microvascular disorders, the most common being chronic venous insufficiency (CVI), alone or with peripheral artery disease (PAD) or microangiopathy. Despite different causes, chronic vascular-origin wounds share similar biological traits and require the same physiological processes for healing.\n\nVascular issues hinder blood perfusion, reducing oxygen, nutrients, and growth factors, leading to decreased energy metabolism and impaired cell functions necessary for proliferation, extracellular matrix production, angiogenesis, and tissue regeneration. Reduced blood supply also limits leukocyte function, compromising the immune response and leading to persistent inflammation and infection. Consequently, these wounds cannot effectively heal, showing prolonged inflammation, persistent infections, and cellular senescence.\n\nBest practice wound care includes compression therapy and physical activity for venous ulcers, and angioplasty, surgery, or bypass for arterial ulcers. These treatments aim to improve blood flow, reduce venous stasis, and enhance venous return. Compression therapy and physical activity lower hydrostatic pressure in the lower limb, while angioplasty and surgery remove arterial blockages or create new blood flow routes.\n\nRecent studies highlight the role of mechano-sensitive (MS) ion channels in skin cell processes and their dysfunction in dermatological disorders. Magnetic stimulation can activate MS TRCP1 channels, enhancing mitochondrial respiration and mitochondriogenesis via the Ca2+\u002FCalModulin(CaM)\u002FNFAT\u002FPGC-1α pathway. Ca2+-activated calmodulin also catalyzes nitric oxide (NO), promoting vasodilation and tissue perfusion.\n\nBimodal red and near-infrared photobiomodulation can further increase mitochondrial respiration and ATP production by activating Cytochrome C oxidase and mitigating NO-induced downregulation. This synergistic mechanism of concurrent optical and magnetic stimulation (COMS) may amplify Ca2+ and NO-mediated processes like cell proliferation, migration, vasodilation, and angiogenesis while resolving inflammation. Thus, COMS may offer a promising therapy for chronic, inflammation-prone wounds.\n\nThe effectiveness of COMS has yet to be validated in large-scale studies. This proposal aims to assess the impact of COMS therapy combined with standard care versus standard care alone on healing, wound closure, recurrence, pain, quality of life, economic outcomes, and device usability in patients with venous leg ulcers (VLU) and VLU associated with PAD in a large-scale multicentric randomized controlled trial.",[114,28,115],"Venous Leg Ulcer","Magnetic Field Exposure",[117,118,119],"Venous leg ulcer","optical stimulation","magnetic stimulation","2026-05-04",{"date":122,"type":36},"2026-05-08",{"date":124,"type":36},"2025-10-01",{"date":126,"type":21},"2026-09-30",{"name":128,"class":43},"Sebastian Probst",10,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":136,"minAge":18,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100633360","vacuum-sealing-drainage-vsd-in-promoting-wound-healing-and-reducing-complications-in-post-infected-obstetric-and-gynecological-surgical-sites-100633360","NCT07525674","Vacuum Sealing Drainage (VSD) in Promoting Wound Healing and Reducing Complications in Post-Infected Obstetric and Gynecological Surgical Sites","Inclusion Criteria:\n\n* Diagnosis of a surgical site infection (SSI) following an obstetric or gynecological surgical procedure (e.g., Cesarean section, hysterectomy, myomectomy, salpingo-oophorectomy).\n* Wound classification as superficial incisional SSI, deep incisional SSI, or organ\u002Fspace SSI (if accessible for VSD application).\n* Willingness and ability to provide informed consent.\n* Wound requiring secondary intention healing or delayed primary closure after debridement\n\nExclusion Criteria:\n\n* Patients with necrotic tissue.\n* Presence of exposed blood vessels, organs, or anastomotic sites where VSD is contraindicated.\n* Untreated coagulopathy or active bleeding diathesis.\n* Allergy to VSD components or dressing materials.\n* Patients with significant immunosuppression (e.g., uncontrolled HIV, organ transplant recipients on high-dose immunosuppressants).\n* Patients with malignant wounds.\n* Patients who decline participation.\n* Patients requiring immediate primary wound closure without debridement.\n* Patients with a known history of severe psychiatric illness affecting compliance.","FEMALE","70 Years",{"count":139,"type":21},30,[24],"This study aims to evaluate the efficacy of VSD in promoting wound healing and reducing complications, such as re-infection, prolonged hospitalization, and need for further surgical interventions, in obstetric and gynecological patients who have developed surgical site infections following their primary procedures. The investigators hypothesize that VSD will lead to faster wound healing, fewer complications, and improved patient outcomes compared to conventional wound care in this specific patient population.",[28],"2026-04-13",{"date":145,"type":36},"2026-04-16",{"date":147,"type":21},"2026-04-20",{"date":149,"type":21},"2027-04-20",{"name":151,"class":43},"Minia University",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":71},"100527635","medical-honey-for-wound-treatment-in-intensive-care-micara-randomized-controlled-single-center-pilot-study-100527635","NCT06150326","Medical Honey for Wound Treatment in Intensive Care. (MICARéa) Randomized, Controlled, Single-center Pilot Study.","MICAREA","Inclusion Criteria:\n\n* Hospitalization in surgical intensive care unit A -USC PTO CHU ANGERS\n* Informed consent signed by patient or relative (or emergency inclusion procedure)\n* Patient with one or more wounds ≥ 4 cm2, evolving for less than 8 days, including: stage 2, 3, 4 pressure sores, lacerations, ulcers, dermabrasions and scar disunions.\n\nExclusion Criteria:\n\n* Patients with honey intolerance\u002Fallergy to bee stings\n* Patients with wounds lasting more than 8 days\n* Patient with a bleeding wound,\n* Patient with a tunneled wound\n* Patients with chronic dermatoses\n* Patient with an estimated life expectancy \\\u003C 15 days\n* Expected discharge ≤48 hours.\n* No affiliation to a French social security scheme or beneficiary of such a scheme.\n* Pregnant, breast-feeding or parturient woman\n* Person deprived of liberty by judicial or administrative decision\n* Person subject to a legal protection measure",{"count":160,"type":21},60,[24],"Wound management is a real public health issue in France. To date, a wide range of devices exists to treat these wounds, depending on their nature and stage of evolution. Honey has been proposed for the care of wounds and is effective in reducing the surface of wounds and the pain perceived by patients. Inanition, its use is very simple compared to usual care, requiring different types of dressing accross time. In the intensive care unit, patients are prone to suffering or developing numerous types of wound, but the interest of honey has not been investigated yet.\n\nWe propose a prospective, monocentric, randomized, single-blind, controlled clinical trial to assess the efficacy of managing acute cutaneous wounds with honey (Activon®) compared with standard care, in intensive care patients. The primary endpoint is the percentage of wound surface area reduction measured at 15 days from inclusion.",[28,164],"Critical Illness",[166],"HONEY","2026-03-31",{"date":169,"type":36},"2026-04-06",{"date":171,"type":36},"2024-06-11",{"date":173,"type":21},"2028-04",{"name":175,"class":176},"University Hospital, Angers","OTHER_GOV",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":195,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":71},"100618245","healing-electroceutical-dressing-for-the-recovery-of-open-wounds-hero-100618245","NCT07329114","Healing Electroceutical Dressing for the Recovery of Open Wounds (HERO)","Prospective, Unblinded, Randomized, Controlled Investigation to Evaluate the Clinical Efficacy of PowerHeal™ Bioelectric Bandage in Managing Infected Traumatic Wounds","HERO","Inclusion Criteria:\n\n1. Female and male participants 18-105 years of age\n2. Hospital admission (or boarding in an emergency department or other area awaiting hospital admission) at participating clinical sites in Ukraine\n3. At least one infected traumatic wound(s) between 20-40 cm2 in size. Probable or confirmed wound infection(s) will be determined by on-site physicians' clinical judgment and the presence of two or more of the following clinical indicators of wound infection:\n\n   1. Presence of worsening pain (from the moment of injury)\n   2. Erythema (redness)\n   3. Warmth (heat)\n   4. Edema (swelling)\n   5. Purulent exudate (drainage)\n   6. Delayed healing\n   7. Discoloration\n   8. Friable granulation\n   9. Foul odor\n   10. Wound margin breakdown or necrosis with or without fever\n   11. Pustules, vesicles, boils\n4. Participant or legal representative provides written informed consent prior to investigation procedures\n5. Participant understands and agrees to adhere to planned investigation procedures\n\nExclusion Criteria:\n\n1. Allergy to silver or zinc\n2. Women who are pregnant or nursing\n3. Women of childbearing potential without a documented negative pregnancy test during the current hospitalization or women of childbearing potential who refused pregnancy testing during screening\n4. Sponsor or contract research organization (CRO) staff directly involved in the conduct of the investigation, and site staff supervised by the investigator, and their respective family members\n5. \\> 60 days from the initial traumatic injury\n6. Known prisoner\n7. The patient is expected to be discharged from the hospital within the next 24 hours\n8. Medical condition other than the acute traumatic wound (and its manifestations) that is likely to result in death within 14 days of randomization\n9. Moribund condition, defined as life expectancy less than 48 hours from randomization\n10. Patients undergoing comfort care measures only such that treatment focuses on end-of-life symptom management over prolongation of life\n11. Expected inability or unwillingness to participate in study procedures\n12. In the opinion of the investigator, participation in the investigation is not in the best interest of the patient\n\nNote: Allergies to parabens and acrylates will also be considered. While they are not direct exclusions, participants with these allergies should avoid being enrolled.","105 Years",{"count":187,"type":21},150,[24],"The goal of this clinical trial is to determine whether the wireless electroceutical dressing (WED) called PowerHeal™ Bioelectric Bandage, improves care of infected wounds by clearing the infection and helping the wound heal better.\n\nThe main hypotheses it aims to answer are:\n\n1. WED promotes wound closure, as determined by wound area measurement\n2. WED manages wound infection in civilian and military wounds in Ukraine, as determined by clinical assessment of wound infection by measuring the numbers and types of relevant microbes.\n\nResearchers will compare to see if PowerHeal™ Bioelectric Bandage the dressing used in the SOC group\n\nParticipants will get their dressings changed per the protocol, wound image and swab will be taken.",[28,191,192,193,194],"Wound Infection","Wound Healing Delayed","Wound of Skin","Infections",[196],"bandage","2026-03-04",{"date":199,"type":36},"2026-03-06",{"date":201,"type":36},"2026-02-11",{"date":203,"type":21},"2027-08",{"name":205,"class":43},"Chandan Sen",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":219,"conditions":220,"keywords":225,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":44},"100559376","phase-2-guselkumab-in-the-treatment-of-adults-with-pyoderma-gangrenosum-pg-100559376","NCT06563323","Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)","A Single-arm Open-label Study Assessing Short-term (Week 6, 16) and Long-term (Week 32) Efficacy of Guselkumab in Adult Participants With Pyoderma Gangrenosum","GEORGE","Inclusion Criteria:\n\n* Willingness to comply with study procedures\u002Frequirements\n* Capable of giving informed consent\n* Diagnosis of at least one PG ulcer by clinical, histological and laboratory assessments with a minimum wound size of 4 cm2.\n* Undergoing at least once a week standard of care wound care at home or at a wound care facility\n* Are candidate for systemic therapy. Must be on a stable dose of prednisone of 20 mg\u002Fday for at least two weeks prior to first drug administration.\n* Males ages 18-99 who agree to not father a child or donate sperm while on study and at least 12 weeks following last dose of the study drug. If subject is sexually active male and could cause pregnancy, subject much be sure that female partner(s) are using birth control that works well or not have sex.\n* Females ages 18-99; either of non-childbearing potential or of childbearing potential who test negative for pregnancy and agree to use at least two reliable methods of birth control or remain abstinent during the study for at least 12 weeks following the last dose of guselkumab.\n* Willingness to travel to study site for all study visits or living \\>30 miles from study site and willing\u002Fable to participate in remote videoconferencing visits with access to a computer with internet and webcam capabilities.\n* Be willing to undergo perilesional and non-lesional skin biopsy at week 0 and week 32 resulting in 4 biopsies during the course of the study. Participants can choose if they are willing to provide 2 additional biopsies at week 16. Refusal to give consent for any of the optional research samples does not exclude participant from participation in the study.\n\nExclusion Criteria:\n\n* Has previously received at any time any therapeutic agent directly targeted to IL-23 including, but not limited to, guselkumab, risankizumab, tildrakuzumab, or mirikizumab\n* Any drug treatment specifically for PG including but not limited to biologics (or biosimilar of), experimental antibodies, small molecules and oral immunosuppressives used within washout periods specified below, prior to first dose of study drug:\n\n  1. 12 weeks for ustekinumab, ixekizumab, secukinumab, brodalumab;\n  2. 8 weeks for infliximab;\n  3. 6 weeks for adalimumab;\n  4. 4 weeks for cyclosporine A, etanercept, inhibitors of the JAK\u002FTYK pathway and PD4 inhibitors;\n  5. 2 weeks for Calcineurin inhibitor topicals (including but not limited to pimecrolimus and tacrolimus) and other advanced topicals (including but not limited to roflumilast and tapinarof).\n\nIf not specified specifically, a time of 4 weeks or 5 half-lives of the drug (whichever is longer) prior to first drug administration.\n\n* Intralesional corticosteroids within 4 weeks of screening.\n* Active clinically infected ulcers. Individuals will be eligible for enrollment following completed treatment and resolution of infection. Antibiotics for wound superinfection are allowed.\n* Immunomodulating medications for managing underlying comorbidities associated with PG, but not PG itself (e.g., for irritable bowel disease (IBD) or rheumatoid arthritis), are allowed as combination therapy except for Methotrexate (MTX) and Leflunomide which are allowed individually but not in combination.\n* Concurrent skin disease that is deemed to interfere with assessment of ulcer.\n* Have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly or a history of lymphoproliferative disease within 5 years before screening; or currently has a known malignancy or has a history of malignancy within 5 years before screening, with the exception of a nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study drug administration or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study drug administration.\n* Recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting. Uncontrolled hypertension - confirmed systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mm Hg.\n* Clinically significant (per investigator's judgement) drug or alcohol abuse within the last 6 months preceding the Baseline Visit.\n* Has not fully recovered from major surgery (e.g., requiring general anesthesia and hospitalization) within 8 weeks before screening, or has such surgery planned during the time the participant is expected to participate in the study (40 weeks) which in the opinion of the investigator would pose an unacceptable risk to the subject.\n* Presence of significant uncontrolled respiratory, hepatic, renal, endocrine, hematologic, neurologic, or neuropsychiatric disorders, or abnormal laboratory screening values that, in the opinion of the investigator, pose an unacceptable risk to the subject if participating in the study or of interfering with the interpretation of the data.\n* Have clinical laboratory test results at screening that are outside the normal reference range of the population and are considered clinically significant, or have any of the following specific abnormalities: Neutrophil count \\\u003C1500 cells\u002FµL, Lymphocyte count \\\u003C500 cells\u002FµL, Platelet count \\\u003C100,000 cells\u002FµL, AST or ALT or alkaline phosphatase \\> 2 times the upper limit of normal, Hemoglobin \\\u003C10 g\u002FdL, Serum creatinine ≥1.5 mg\u002FdL (SI: ≤137 μmol\u002FL), White blood cells \\\u003C3500 cells\u002F µL\n* Participant has known allergies, hypersensitivity, or intolerance to guselkumab or its excipients.\n* Individuals who are pregnant, lactating or breastfeeding.\n* History of chronic or recurrent infections, or active, untreated, acute infection, or immunocompromised to an extent that participation in the study would pose an unacceptable risk to the subject based on the investigator's clinical assessment.\n* Clinically serious infection or received intravenous antibiotics for an infection, within 8 weeks before first dose.\n* Have signs or symptoms suggestive of active Tuberculosis (TB) upon medical history and\u002For physical examination. An exception is made for participants who are currently receiving treatment or will initiate treatment for latent TB prior to first administration of study intervention. For participants with a history of treated latent TB there must be documentation of appropriate treatment prior to the first administration of study intervention.\n* Positive for human immunodeficiency virus (HIV), active hepatitis B virus, or hepatitis C virus. A positive Hepatitis B surface antibody test with a corresponding negative hepatitis B surface antigen test indicates immunity to the disease and will not be exclusionary.\n* Symptomatic herpes zoster infection within 12 weeks of screening or recurrent or disseminated (even a single episode) herpes zoster.\n* Symptomatic herpes simplex or disseminated (even a single episode) herpes simplex at the Week 0 (baseline) visit.\n* History of disseminated opportunistic infections (e.g., listeriosis and histoplasmosis).\n* Have received a live vaccine within 12 weeks prior to baseline or intend to have a live vaccine during the course of the study or 4 weeks after last study drug administration or 12 weeks after last study drug administration for Bacillus Calmette-Guérin (BCG) vaccine.\n* Have any other condition that precludes the subject from following and completing the protocol, in the opinion of the investigator.\n* Are investigator site personnel directly affiliated with this study and\u002For their immediate families (spouse, parent, child, or sibling).\n* Are currently enrolled in, or discontinued from a clinical trial involving an investigational product or non-approved use of a drug or device within the last 4 weeks or a period of at least 5 half-lives of the last administration of the drug, whichever is longer, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.","99 Years",{"count":216,"type":21},17,[218],"PHASE2","A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)",[221,222,28,223,224],"Pyoderma Gangrenosum","Skin Diseases","Pyoderma","Skin Ulcer",[226,227],"Guselkumab","IL-23 Inhibitor",{"date":199,"type":36},{"date":230,"type":36},"2025-02-01",{"date":232,"type":21},"2027-08-13",{"name":234,"class":43},"Oregon Health and Science University",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":71},"100580740","randomized-controlled-trial-on-the-efficacy-and-safety-of-xiang-lei-ointment-in-diabetic-related-ulcer-management-100580740","NCT06841237","Randomized Controlled Trial on the Efficacy and Safety of Xiang Lei Ointment in Diabetic-related Ulcer Management","Inclusion Criteria:\n\n* a confirmed diagnosis of type 1 or type 2 diabetes mellitus that meets the standard World Health Organization definition, with blood glucose controlled prior to enrolment and a glycated haemoglobin HbA1c level of less than 10%;\n* the type of wound is an ulcer;\n* the wound etiology is diabetic, mainly abnormalities in blood glucose, resulting in poor or prolonged healing and requiring standard wound therapy;\n* the staging of the wound is in the granulation phase;\n* voluntary participation in the study and signing of an informed consent form.\n\nExclusion Criteria:\n\n* acute heart attack, heart failure, hepatitis, shock, expiratory failure and other serious diseases that have not been corrected;\n* uncontrolled blood glucose, fasting blood glucose \\> 15 mmol\u002FL and glycated haemoglobin \\> 12%;\n* active bleeding in the wound, which does not allow the implementation of the conventional basic treatment plan;\n* serum albumin \\< 20 g\u002FL; haemoglobin \\< 60 g\u002FL; platelets \\< 50 x 109\u002FL;\n* a state of disseminated infection that is being or will be treated with antibiotics\n* patients with advanced malignant tumours;\n* active autoimmune disease;\n* previous allergy to topical human granulocyte macrophage stimulating factor gel (Jinfuning);\n* inability of the patient to co-operate or mental disorder;\n* in the judgement of the investigator, the subject has a clearly irremovable cause of wound healing, is unsuitable for the study or is unable to comply with the requirements of the study.","80 Years",{"count":243,"type":21},56,[24],"Diabetes is one of the major chronic diseases. Diabetic ulcers are important adverse outcomes of diabetes. Approximately 80% of lower - limb amputations are caused by diabetic foot ulcers, which are the main causes of disability and death among patients. Moreover, it places a huge burden on the medical insurance system. Currently, there are western medicine treatment guidelines for diabetic foot, yet the clinical efficacy is less than satisfactory. The amputation rate caused by diabetic foot ulcers continues to rise every year. There is an urgent clinical need for novel and effective intervention measures to address this disease.\n\nMacrophages are important cells involved in the inflammatory and proliferative phases of wounds, playing a crucial role in wound repair and reconstruction. Diabetes can cause wounds to remain in the pro - inflammatory stage continuously, leading to the aggregation of M1 macrophages and preventing their timely transformation into the pro - proliferative and repair stage. As a result, wounds exhibit persistent chronic inflammation and delayed tissue proliferation or remodeling.\n\nXianglei Tangzu Ointment is a natural medicine approved for marketing by the National Medical Products Administration in November 2023. Its ingredients include Pogostemon cablin extract and asiaticoside. Research shows that the plant components in Xianglei Tangzu Ointment can promote the transformation of M1 macrophages into M2 macrophages, thereby reducing the inflammatory response and accelerating the proliferative repair of diabetic wounds. It has achieved certain curative effects in the clinical treatment of promoting wound healing. In order to use Xianglei Tangzu Ointment more precisely, accumulate clinical evidence - based medicine evidence, and explore the effectiveness and safety of Xianglei Tangzu Ointment in treating diabetic ulcers under the guidance of the chronic wound staging theory, clinical evidence - based medicine evidence needs to be obtained.",[247,191,28],"Diabetic Wound","2026-02-26",{"date":250,"type":36},"2026-03-02",{"date":252,"type":36},"2025-04-10",{"date":254,"type":21},"2027-02-15",{"name":256,"class":43},"Peking University Third Hospital",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":268,"conditions":269,"keywords":276,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":291},"100570426","phase-3-tissue-repair-gel-in-venous-leg-ulcers-us-100570426","NCT06707090","Tissue Repair Gel in Venous Leg Ulcers (US)","A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)","TRIVIA","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* Participants considered nutritionally deficient.",{"count":266,"type":21},312,[83],"The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.",[114,270,271,272,28,273,274,275],"Venous Ulcer","Venous Stasis Ulcer","Venous Stasis","Wounds","Venous Insufficiency of Leg","Non-healing Wound",[277,278,279,280,281],"Tissue Repair","Glucoprime","TR Therapeutics","Debridement","VLU","2026-02-09",{"date":284,"type":36},"2026-02-12",{"date":286,"type":36},"2025-01-28",{"date":288,"type":21},"2028-02",{"name":279,"class":290},"INDUSTRY",33,{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":44},"100556233","hyaluronic-acid-and-octenidine-gel-as-an-adjunct-to-non-surgical-periodontal-treatment-100556233","NCT06522438","Hyaluronic Acid and Octenidine Gel as an Adjunct to Non-surgical Periodontal Treatment","Early Healing Dynamics and Microbial Changes Following the Use of a Novel Thermosensitive Gel With Hyaluronic Acid and Octenidine as an Adjunct to Non-surgical Periodontal Treatment","Inclusion Criteria:\n\n* Male or female aged 18 and above\n* Engaged patients presenting with a Full Mouth Plaque Score (FMPS) of ≤ 20% within the 6 weeks prior to enrolment, or exhibiting a ≥ 50% reduction in plaque score from the initial screening visit.\n* Periodontitis stage III\u002FIV (grades A to C) with at least one site per quadrant with PPD ≥5mm, bleeding on probing and attachment loss ≥5mm\n* Willing to sign informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Know hypersensitivity and\u002For allergy to any of the product's component (as per user leaflet)\n* Self-reported pregnancy or lactation\n* Smoking (current or in past 5 years), including e-cigarettes\u002Fvaping\n* Medical history including diabetes mellitus or other serious medical\u002F psychiatric conditions or transmittable diseases that according to the investigator may increase the risk associated with study participation\n* History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures or\u002Fand systemic antibiotic therapy during the 3 months preceding the baseline evaluation\n* In chronic treatment with anti-inflammatory (including corticosteroids), anticoagulants\u002Fantiplatelets (including aspirin), immunosuppressants or other medication that can severely impact wound healing\n* History of alcohol or drug abuse\n* Subgingival professional mechanical plaque removal (excluding not-extensive subgingival debridement as judged by the examining clinician) and\u002For surgical periodontal treatment within the last 12 months\n* Other severe acute or chronic medical or psychiatric condition or psychological disorder, including limited mental capacity or language skills such that study information could not be understood, informed consent could not be obtained, or simple instructions could not be followed, or any additional conditions which, in the judgement of the investigator, would make the subject inappropriate for entry into this trial",{"count":300,"type":21},26,[24],"This parallel-group, pilot study will test the hypothesis that the adjunctive use of a thermosensitive gel containing Hyaluronic Acid (HA) and Octenidine to non-surgical periodontal treatment (NSPT) will be able to modulate the early wound healing events. This will be assessed through the expression of specific gingival crevicular fluid markers, as well as by changes in gingival blood flow (assessed by laser speckle contrast imaging), bacterial load, soft tissues contour, clinical parameters and patient-reported outcomes.\n\nThe study will involve up to 26 patients and will take place at the Centre for Oral Clinical Research (COCR), at the Institute of Dentistry, Faculty of Medicine and Dentistry, Queen Mary University of London under The Royal London Dental Hospital, Barts Health NHS Trust. Patients will be randomised to receive either NSPT alone or NSPT+ HA and Octenidine gel, and will be followed up to 3 months after treatment.\n\nThe study will consist of 7- 8 visits.",[304,28,30,29,31],"Periodontitis",[306,307,308,309],"Hyaluronic Acid","Octenidine","Biomarkers","Non-surgical periodontal treatment","2026-02-03",{"date":312,"type":36},"2026-02-05",{"date":314,"type":36},"2025-06-03",{"date":316,"type":21},"2027-12-31",{"name":42,"class":43},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":343},"100609038","edx110-randomized-control-trial-for-treatment-of-dfus-100609038","NCT07209358","EDX110 Randomized Control Trial for Treatment of DFUs","A Multi-Centre, Observer-Blinded, Randomized Controlled Trial of EDX110 for the Treatment of Diabetic Foot Ulcers","Inclusion Criteria:\n\n* Participants at least 18 years old and willing to participate in all procedures and follow-up evaluations necessary to complete the study.\n* The participant must have an index ulcer meeting the following characteristics:\n\n  1. Non-healing DFU defined as; at least 4 weeks prior to enrolment the ulcer has failed to progress on a healing trajectory.\n  2. Full-thickness wound; defined as Wagner Diabetic Foot Ulcer Grade 1 - superficial ulcer of skin or subcutaneous tissue.\n  3. Located on the anatomical foot; defined as distal to the medial or lateral malleolus.\n* Presents with or without clinical signs of superficial infection. Infection is defined using International Working Group of the Diabetic Foot (IWGDF) PEDIS classification and for the purpose of inclusion infections must be PEDIS grade 1 (Mild); Infected: At least two of these items are present: Local swelling or induration Erythema \\>0.5 but \\\u003C2 cm2 around the wound, Local tenderness or pain, Local increased warmth, Purulent discharge.\n* Ulcer duration at randomization must be present for ≥1 month but less than \\\u003C24 months in duration.\n* Post-debridement wound area is ≥0.1 cm2 and ≤25 cm2.\n* If two or more ulcers either mono or bilateral are present, the index ulcer must additionally be:\n\n  1. The ulcer with the largest wound area, as long as it meets all other criteria.\n  2. ≥3cm distance from any other ulcer on the affected limb\n* Known history of type 1 or type 2 diabetes (confirmed by the subject's medical history).\n* HgbA1c \\\u003C12% (NGSP) OR 108 mmol\u002Fmol (IFCC) OR average blood glucose 298 mg\u002FDL.\n* Participant has adequate circulation to the affected extremity as defined by Wound, Ischemia, foot Infection (WIfI) Ischemia grades 0-1 (no PAD to Mild PAD).\n* Participants are required to have either.\n\n  1. Ankle-Brachial Index (ABI) by Doppler: ≥0.6 OR Toe-Brachial Index (TBI) ≥ 0.5\n  2. OR Dorsum transcutaneous oxygen test (TcPO2): \\>40 mm\u002FHg\n\nExclusion Criteria:\n\n* Participants with wounds that have any of the following characteristics:\n\n  1. Wagner Grade 2 - ulcers extend into tendon, bone, or capsule\n  2. Grade 3 - deep ulcer with osteomyelitis, or abscess\n  3. Grade 4 - partial foot gangrene\n  4. Grade 5 - whole foot gangrene\n* Infections that are classified as:\n\n  1. PEDIS 3 (Moderate): Infection with no systemic manifestations and involving: Erythema extending ≥2 cm2 from the wound margin, and\u002For tissue deeper than skin and subcutaneous tissues (e.g., tendon, muscle, joint, and bone).\n  2. PEDIS 4 (Severe): All of the above in PEDIS 3 plus manifestations (of the systemic inflammatory response syndrome \\[SIRS\\]).\n  3. In addition, any diabetic foot infections with; Confirmed underlying bone involvement (osteomyelitis) based on; imaging (plain X-ray, CT or MRI), clinical examination (exposed bone or positive probe to bone test) or culture\u002Fhistopathology of a bone specimen\n  4. OR Cellulitis\u002Flymphangitis\u002Fsoft tissue gas or necrotizing fasciitis originating from the wound site.\n* Tunnelling, Cavity or undermining wounds.\n* Known or suspected local skin malignancy at the site of the ulcer.\n* A wound that is actively bleeding. This does not exclude enrollment once active bleeding has stopped (hemostasis).\n* Gross Foot deformities that would interfere with proper off-loading or proper wound healing i.e. non-active charcot foot, rocker bottom foot, gross digital deformities.\n* Active Charcot deformity.\n* Wound duration \\>2 years.\n* Participants receiving any of the following prior therapies. In the last 30 days:\n\n  1. Has required systemic corticosteroids \\>10mg\u002Fkg\u002Fday OR\n  2. Participant has required Chemoradiation (chemotherapy and\u002For radiation therapy) to treat cancer and is immunocompromised OR\n  3. Participant is anticipated to require such medications during the study period.\n  4. Study ulcer treatment with any advanced therapy, including, biomedical or topical growth factors, tissue engineered materials (e.g., Apligraf or Dermagraft), sterilized placental allografts (EpiFix, NovaFix, etc.), or other scaffold materials (e.g., OASIS® Wound Matrix, MatriStem Wound Matrix).\n  5. Has undergone any amputation to the affected leg.\n* Known hypersensitivity to constituents of the product.\n* Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of, or compliance with the study protocol in the judgement of the Investigator.\n* Women of childbearing age (women aged \\\u003C55 years who have not undergone menopause) who are:\n\n  1. Pregnant at time of enrolment\n  2. Breast-feeding\n* Concurrent enrolment in any other study.","90 Years",{"count":327,"type":21},298,[24],"Prospective, multi-centered, observer blinded, pre-market study, 1:1 randomized control trial, to determine if addition of EDX110 dressing system to standard of care leads to an improvement in diabetic foot ulcers healing compared to just using standard of care.",[28,331],"Diabetic Foot Ulcer",[333],"Hard to heal wounds","2025-12-15",{"date":336,"type":36},"2025-12-17",{"date":338,"type":36},"2025-10-30",{"date":340,"type":21},"2026-12-31",{"name":342,"class":290},"ConvaTec Inc.",4,{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":350,"maxAge":241,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":71},"100613047","an-exploratory-research-on-the-efficacy-and-safety-of-antibacterial-absorbable-dressing-in-chronic-non-healing-wounds-100613047","NCT07261501","An Exploratory Research on the Efficacy and Safety of Antibacterial Absorbable Dressing in Chronic Non-healing Wounds","Inclusion Criteria:\n\n* Age : 18-80 years\n* Wound Type : Chronic non-healing ulcers\\* with no signs of healing progression for ≥1 week\n* Wound Area : 1-35 cm²\n* Infection Status : Local infection, contamination, or colonization\\*\\* as classified by IWII Wound Infection Staging\n* Wound Phase : Late necrotic stabilization phase, granulation phase, or epithelial migration phase\\*\\*\\*\n* Consent : Voluntary participation with signed informed consent\n\nExclusion Criteria:\n\n* Severe Comorbidities : Acute myocardial infarction, heart failure, hepatitis, shock, respiratory failure, or other critical conditions requiring stabilization\n* Uncontrolled Diabetes : Fasting blood glucose \\>15 mmol\u002FL or HbA1c \\>12%\n* Active Wound Hemorrhage : Bleeding precluding standard wound therapy\n* Critical Laboratory Values :\n\nSerum albumin \\\u003C20 g\u002FL Hemoglobin \\\u003C60 g\u002FL Platelet count \\\u003C50×10⁹\u002FL\n\n* Systemic Infection : Disseminated\u002Fsystemic infection requiring antibiotic therapy\n* Malignancy : Advanced cancer patients，Current radiotherapy\u002Fchemotherapy，Malignant (cancer-related) ulcers\n* Untreated Burns : Full-thickness (third-degree) burns without escharotomy\n* Active Autoimmune Disease : Flare-up phase of autoimmune disorders\n* Pregnancy\u002FLactation : Pregnant or breastfeeding women\n* Allergy : Hypersensitivity to absorbable wound repair materials or polyhexamethylene biguanide hydrochloride\n* Non-compliance : Inability to cooperate or psychiatric disorders\n* Investigator's Discretion : Any condition deemed to compromise wound healing or study adherence","18 Months",{"count":139,"type":21},[24],"Antimicrobial absorbable wound dressing is a novel polyester-based degradable dressing. Previous preclinical studies have demonstrated promising efficacy, with a 3-week wound area reduction rate of 63.53% in large animal models, outperforming foreign counterparts (49.47%), without significant adverse reactions observed during application. Toxicological risk assessment confirms acceptability, and small animal model studies show no abnormalities in toxicity or sensitization. However, current evidence lacks clinical validation, particularly regarding efficacy and safety in chronic non-healing wounds.\n\nThis study integrates modern clinical evaluation methods with chronic wound staging theory to systematically investigate the effectiveness and safety of antimicrobial absorbable wound repair materials in treating chronic non-healing wounds. The research aims to identify optimal indications and provide robust evidence for its clinical efficacy and safety.",[28,192],"2025-11-22",{"date":357,"type":36},"2025-12-03",{"date":359,"type":36},"2025-11-01",{"date":361,"type":21},"2026-11-01",{"name":256,"class":43},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":17,"minAge":370,"maxAge":371,"enrollmentInfo":372,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":71},"100610641","phase-1-effect-of-evfv-on-wound-healing-in-dystrophic-epidermolysis-bullosa-100610641","NCT07230223","Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa","Safety and Efficacy of Ev.FV in Epidermolysis Bullosa Patients, A Randomized Clinical Trial, Phase 1 , 2","Inclusion Criteria:\n\n* DEB participants determined by electron microscopy, or genetic testing. Individuals with severe DEB (eg, RDEB patients with an absence of collagen VII) and milder forms of DEB (eg, RDEB patients with reduced levels of collagen VII) will be eligible.\n* People with one or more active wounds (each between 10 and 50 square centimeters on the arms, legs or trunk.)\n* Participants must be willing to comply with the requirements of the protocol and have consent to participate in the project.\n* Participants must be negative in the urine drug screening visit.\n\nExclusion Criteria:\n\n* Participants with clinical evidence of systemic infection.\n* Participants have a history of bone marrow transplantation.\n* Participants must have evidence of autoimmune disease, including insulin-dependent diabetes.\n* Participant has evidence of significant wound healing prior to treatment (ie, wound closure ≥ 20% during treatment at the first observation period).\n* Participant has a severe medical condition, such as malignancy (including skin cancer), life expectancy less than 2 years, which limits movement to the clinical center.\n* Participants have a current history of alcohol or substance abuse or a history of alcohol or substance abuse that requires treatment in the past 12 months.\n* People participating in the screening should have a positive hepatitis and human immunodeficiency virus (HIV) test result.\n* Women who are pregnant, lactating or planning to become pregnant during the study\n* Women who are of reproductive age and use birth control pills.","3 Years","35 Years",{"count":53,"type":21},[55,218],"Epidermolysis bullosa (EB) is a hereditary disease of skin tissues that causes painful bleeding blisters in the skin and mucous membrane. The prevalence of this disease is 1 in 50,000. The severity of the disease varies depending on the type of disease and may even lead to death. This disease is caused by a genetic mutation in keratin or collagen, and its incidence is the same in all men and women of different human races. In these patients, the skin becomes extremely fragile and peels off with the slightest scratch. Many blisters are one of the most obvious symptoms of this disease. The possibility of skin cancer in people suffering from this disease is more than others.\n\nNowadays, the preference of cell therapy methods is to use biological products produced by cells such as extracellular vesicles and mitochondria instead of stem cells. The use of Extracellular vesicles and engineered EVs as messenger carriers can introduce a new treatment method based on cell products for skin regeneration and as an alternative to cell therapy.\n\nTherefore, in this study, EV.FV will be applied topically to patients.",[376,28],"Dystrophic Epidermolysis Bullosa","2025-11-14",{"date":379,"type":36},"2025-11-17",{"date":381,"type":36},"2024-01-09",{"date":383,"type":21},"2026-12-25",{"name":385,"class":43},"Isfahan University of Medical Sciences",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":22,"phases":396,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":71},"100452308","early-phase-1-micronanobubbles-mnbs-for-treatment-of-acute-and-chronic-wounds-100452308","NCT05169814","Micro\u002FNanobubbles (MNBs) for Treatment of Acute and Chronic Wounds","Micro\u002FNanobubbles (MNBs) and Wound Therapy: A Pilot Study Involving a Novel Oxygen Delivery System for Treatment of Acute and Chronic Wounds","MNB","Inclusion Criteria:\n\n* are above the age of 18.\n* have traumatic, surgical, or chronic wounds.\n* have radiotherapy related tissue injury.\n* have thermal, chemical, and\u002For electrical burn injuries.\n* have pressure ulcers, diabetic foot ulcers, venous ulcers, arterial ulcers, and\u002For neuropathic skin ulcers.\n* have acute ischemic wounds\n\nExclusion Criteria:\n\n* have infected wounds.\n* have wounds with exposed vital structures such as nerves, arteries, and\u002For veins.\n* have wounds associated with malignancy.",{"count":395,"type":21},40,[397],"EARLY_PHASE1","The purpose of this study is to assess the safety and efficacy of Micro\u002Fnanobubbles (MNB's) for the healing of acute and chronic wounds.",[400,28],"Open Wound",[402,403,404,392,405,406,407],"acute wounds","chronic wounds","MNB solution","Micro\u002Fnanobubbles","Micronanobubbles","negative pressure wound therapy with instillation","2025-09-26",{"date":410,"type":36},"2025-10-02",{"date":412,"type":36},"2021-10-09",{"date":414,"type":21},"2027-06-01",{"name":416,"class":43},"University of California, Irvine",{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":423,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":425,"briefSummary":426,"conditions":427,"keywords":429,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":71},"100541692","phase-2-4-aminopyridine-for-skin-wound-healing-100541692","NCT06333171","4-aminopyridine for Skin Wound Healing","Inclusion Criteria:\n\n* Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm.\n* Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination.\n* Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention).\n* Adults subject aged 18-70\n* Ability to give written informed consent.\n* Capable of safely coming in for follow up visits on all scheduled appointments.\n\nExclusion Criteria:\n\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.\n* History of difficult compliance with timely follow up\n* Patients outside the age range\n* Unable to provide informed consent.\n* Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).\n* Patients with a concomitant traumatic brain injury.\n* Patients unable to communicate.\n* Patients unwilling to complete the study requirements.\n* Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.\n* Pregnancy, breastfeeding or incarcerated individuals.\n* Non-English speaking\n* Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds",true,{"count":187,"type":21},[218],"Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults.\n\nThe purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing.\n\nThe investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.",[273,193,28,428],"Wounds and Injuries",[430,431],"4 aminopyridine","wound healing","2025-09-01",{"date":434,"type":36},"2025-09-03",{"date":436,"type":21},"2025-09",{"date":438,"type":21},"2028-03",{"name":440,"class":43},"John Elfar",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":17,"minAge":448,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":22,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":71},"100562672","innoven-efficacy-of-porcine-placental-extracellular-matrix-plus-standard-of-care-soc-versus-soc-alone-100562672","NCT06606210","INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone","An Observer-Blinded Multicenter Randomized Controlled Trial Evaluating Porcine Placental Extracellular Matrix as an Adjunct to Standard of Care Versus Standard of Care Alone in Hard-to-Heal Venous Leg Ulcers","Inclusion Criteria:\n\n1. Subjects must be at least 21 years of age or older.\n2. At randomization subjects must have a target ulcer with a minimum surface area of 1 cm2 and a maximum surface area of 25 cm2 measured post-debridement.\n3. The target ulcer must have been present for a minimum of 4 weeks and cannot have received more than 52 weeks of high-level compression prior to the initial screening visit.\n4. No visible signs of improvement in the four weeks prior to randomization: less than 40% reduction in wound size over the 4 weeks prior to randomization.\n5. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:\n\n   1. ABI between 0.7 and ≤ 1.3;\n   2. TBI ≥ 0.6;\n   3. TCOM ≥ 40 mmHg;\n   4. PVR: biphasic.\n6. If the potential subject has two or more ulcers, they must be separated by at least 2 cm post-debridement. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.\n7. The potential subject must agree to attend the weekly study visits required by the protocol.\n8. The potential subject must be willing and able to participate in the informed consent process.\n\nExclusion Criteria:\n\n1. The potential subject is known to have a life expectancy of \\\u003C 6 months.\n2. The target ulcer exhibits signs or symptoms consistent with clinical infection, requiring topical antibiotic or antimicrobial agents or systemic antibiotic therapy, or there is cellulitis in the surrounding skin.\n3. The target ulcer exposes tendon or bone.\n4. There is evidence of osteomyelitis complicating the target ulcer.\n5. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the Principal Investigator believes will interfere with wound healing (e.g., biologics).\n6. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.\n7. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n8. The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Digital planimetry is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n9. The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.\n10. The potential subject has had a lower extremity Deep Vein Thrombosis (DVT) to either limb within the previous 90 days.\n11. The potential subject is unable to tolerate therapeutic compression (30-40mmHg).\n12. Women who are pregnant or considering becoming pregnant within the next 6 months.\n13. The potential subject has end stage renal disease requiring dialysis.\n14. Participation in another clinical trial involving treatment with an investigational product within the previous 30 days.\n15. A potential subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments.\n16. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.\n17. The potential subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n18. Potential subjects with a sensitivity or allergy to porcine materials or collagen.\n19. Potential subjects with religious or personal objection to use of porcine- or animal-derived materials.\n20. A subject with a disorder that would create unacceptable risk of treatment complications.","21 Years",{"count":450,"type":21},120,[24],"INNOVEN is a multi-center randomized controlled clinical trial to evaluate the efficacy of porcine placental extracellular matrix (PPECM) and standard of care (SOC) versus SOC alone in the closure of non-healing venous leg ulcers (VLUs).",[28,114],"2025-08-21",{"date":456,"type":36},"2025-08-22",{"date":458,"type":36},"2024-09-19",{"date":460,"type":21},"2026-04",{"name":342,"class":290},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":22,"phases":471,"briefSummary":472,"conditions":473,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":480,"locationsCount":4},"100536997","postoperative-wounds-with-delayed-healing-risk-of-clinical-trial-registration-100536997","NCT06272097","Postoperative Wounds With Delayed Healing Risk of Clinical Trial Registration","Optimization Program for the Care Management of Wounds With Delayed Healing Risk After Hip Arthroplasty Based on TIME CDST Tool: a Randomized Controlled Trial Protocol","Inclusion Criteria:\n\n* age ≥18 years;\n* First-time recipient of unilateral total HA or hemiarthroplasty;\n* Postoperative wound healing delay risk, defined as epithelialization \\\u003C50% at 2 weeks postoperatively (quantified using a standardized manual planar measurement method: on day 14 postoperatively, a (quantified using a standardized manual planar measurement method: on day 14 postoperatively, a standardized transparent grid membrane with 1mm² graduations is placed vertically over the wound, and the wound perimeter and epithelialization boundary are marked with a surgical marker. boundary are marked with a surgical marker pen; the epithelialized area is defined as pink, non-exudative tissue completely covering the dermis); Normal cognitive and communication abilities;\n* Ability to comply with relevant nursing measures;\n* Voluntary participation in this trial\n* Voluntary participation in this trial and signed informed consent form.\n\nExclusion Criteria:\n\n* Active infection at the surgical site prior to initial hip surgery; Deep surgical site infection (SSI) or periprosthetic joint infection (PJI) diagnosed or strongly suspected at screening. diagnosed or strongly suspected at screening (based on clinical symptoms, imaging, or aspiration results according to the MSIS\u002FEBJIS criteria);\n* Complete wound dehiscence (\\>2 cm) or exposure of the prosthesis\u002Fbone cement, requiring emergency revision surgery;\n* Severe vascular insufficiency (ABI \\\u003C0.5 cm);\n* Severe acute and chronic chronic disease (ABI \\\u003C0.5 cm) insufficiency (ABI \\\u003C0.6, severe limb ischemia);\n* Uncontrolled systemic conditions severely impairing healing potential: severe malnutrition or obesity (BMI≥ 40 kg\u002Fm² or≤ 16 kg\u002Fm² or serum albumin \\\u003C2.5 g\u002FdL); Uncontrolled diabetes (HbA1c \\>9% in the past 3 months); severe heart failure (NYHA IV); severe liver dysfunction (Child-Pugh C); severe renal failure requiring dialysis; active malignant tumors; immunosuppressive therapy (high-dose corticosteroids \\>10 mg prednisolone); and dose corticosteroids \\>10 mg prednisone equivalent\u002Fday, biologics, or immunosuppressive agents following transplantation).",{"count":470,"type":21},492,[24],"this study aims to optimize the components of TIME CDST based on clinical practice and apply the optimized elements to the management of wounds with delayed healing risk after hip arthroplasty to identify and design the key steps in the clinical application of TIME CDST. Through a randomized controlled trial approach, the investigators will conduct a rigorous comparative analysis of the experimental group and the control group. The intervention group will receive an intervention plan based on the TIME CDST tool led by wound specialist nurses at each dressing change, while the control group receive a routine wound care program of wound cleaning and dressing changes at each dressing change. The main research objective is to evaluate the superiority of the experimental group compared with the control group in terms of wound healing time, healing quality, and patient satisfaction. Through the implementation of this study, the investigators expect to provide an effective optimization scheme for the management of postoperative wounds with delayed healing risk in clinical practice, thereby improving patient outcomes and quality of life.",[28],"2025-07-21",{"date":476,"type":36},"2025-07-25",{"date":478,"type":21},"2025-12-31",{"date":96,"type":21},{"name":481,"class":43},"Danni Feng",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":22,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":504},"100563490","ideal-efficacy-of-porcine-placental-extracellular-matrix-augmented-plus-standard-of-care-soc-versus-soc-alone-for-the-management-of-diabetic-foot-ulcers-100563490","NCT06616844","IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers","Evaluating the Efficacy of Porcine Placental Extracellular Matrix Augmented Wound Care Against Standard Wound Care for the Management of Diabetic Foot Ulcers: A Multi-center, Prospective, Observer-blinded, Randomized Controlled Clinical Trial.","IDEAL","Inclusion:\n\n1. Subjects at least 21 years old. At least 50% of the enrolled population must be \\> 65 years of age.\n2. Known history of type 1 or type 2 diabetes.\n3. The patient must have a target ulcer meeting the following characteristics:\n\n   i. A diabetic ulcer that is either Wagner Grade 1 or Wagner Grade 2 . ii. Located on the anatomical foot; defined as a minimum of 50% of ulcer area extending distal to the medial malleolus.\n\n   iii. The target ulcer must have been present for a minimum of 4 weeks and no longer than 52 weeks.\n\n   iv. The target ulcer must display evidence of delayed wound healing, defined as less than 50% wound area reduction over the four weeks preceding randomization.\n\n   v. At randomization subjects must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 25.0 cm2 measured post-debridement.\n4. If two or more diabetic foot ulcers with the same Wagner Grade are present, the Index ulcer must additionally be:\n\n   i. the ulcer with the largest wound area; ii. ≥ 2cm distant from any other ulcer on the affected limb, post-debridement; iii. the only ulcer to be evaluated by the study (one patient, one wound).\n5. Subject has adequate circulation to the affected extremity, as demonstrated by at least one of the following within the past 30 days i. ABI ≥ 0.7 and ≤ 1.3; ii. TBI ≥ 0.6; iii. TCOM ≥ 40 mmHg; iv. PVR: biphasic.\n6. BMI ≤45\n7. Subject is willing to participate in all procedures and follow-up evaluations necessary to complete the study.\n8. Subject has signed informed consent.\n\nExclusion:\n\n1. The potential subject is known to have a life expectancy of \\<6 months.\n2. Index Ulcers will be excluded if they meet any of the following criteria upon assessment:\n\n   i. Index ulcer determined to be due to a condition other than diabetes ii. Active Charcot deformity OR major structural abnormalities of the foot iii. Known or suspected local skin malignancy to the index diabetic ulcer iv. Wound duration \\>12 months without intermittent closure\n3. The target ulcer exhibits 2 or more of the following signs or symptoms consistent with clinical infection:\n\n   i. erythema that extends ≥ 0.5cm from wound edge ii. local increased warmth iii. purulent exudate iv. local swelling or induration v. local tenderness or pain\n4. Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator\\'s exam or radiographic evidence.\n5. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent), radiation therapy, cytotoxic chemotherapy, or is taking medications that the Principal Investigator believes will interfere with wound healing (e.g., biologics).\n6. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.\n7. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n8. The surface area of the target ulcer, as measured by digital planimetry or manual linear measurements (e.g. with a ruler), decreases by more than 25% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period).\n9. The surface area of the target ulcer, as measured by digital planimetry, decreases by more than 25% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.\n10. The potential subject is unable to adhere to therapeutic offloading, if required by anatomical location of target ulce.\n11. Women who are pregnant or considering becoming pregnant within the next 6 months.\n12. The potential subject has end stage renal disease requiring dialysis.\n13. Participation in another clinical trial involving treatment with an investigational product within the previous 30 days.\n14. A potential subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments.\n15. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.\n16. The potential subject has a malnutrition indicator score \\<17 as measured on the Mini Nutritional Assessment.\n17. Potential subjects with a sensitivity or allergy to porcine materials or collagen will be excluded.\n18. Potential subjects with religious or personal objection to use of porcine- or animal-derived materials will be excluded.\n19. A subject with a disorder that would create unacceptable risk of treatment complications is excluded.\n20. Subjects will be considered ineligible for enrolment if any of the following criteria are met:\n\n    i. Immune system disorders including Systemic Lupus Erythematosus (SLE), Acquired Immunodeficiency Syndrome (AIDS) or HIV.\n\n    ii. In the past 6 months, having undergone a revascularization procedure aimed at increasing blood flow in the target limb OR any amputation affecting the target limb",{"count":491,"type":21},194,[24],"A multi-center, prospective, observer-blinded, randomized controlled clinical trial to evaluate the efficacy of PPECM augmented standard of care versus standard of care alone in the management of hard-to-heal diabetic foot ulcers.",[28,495],"Ulcer","2025-05-16",{"date":498,"type":36},"2025-05-21",{"date":500,"type":36},"2025-02-12",{"date":502,"type":21},"2026-07",{"name":342,"class":290},9,{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":514,"briefSummary":515,"conditions":516,"keywords":521,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":343},"100533242","phase-3-safety-and-efficacy-of-realskin-to-provide-complete-wound-closure-of-burn-wounds-as-an-alternative-to-autografting-100533242","NCT06223269","Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting","A Phase III Open-Label, Multicenter, Randomized, Controlled Clinical Trial to Evaluate the Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Mixed-Depth, Full-Thickness Burn Wounds as an Alternative to Autografting","Inclusion Criteria:\n\n1. The subject, or the subject's legally authorized representative (LAR), provides written informed consent to participate in this study\n2. Males or females age greater than or equal to 18 years old\n3. Total Burn Surface Area (TBSA) \\\u003C50% to include mixed depth and full-thickness burn wounds as defined as \"primarily full-thickness (FT) and deep-partial (DPT) thermal burns (e.g. \\>60% of the total burn area should be FT and DPT) before debridement\", and full-thickness burns for which surgical intervention is clinically indicated\n4. Having a mixed depth thermal burn wound including full thickness requiring skin grafting\n5. Biological females must have a negative serum pregnancy test at Screening and must not be nursing\n6. All subjects must agree to use a protocol-approved method of contraception for a minimum of 3 months following realSKIN placement, which includes a barrier method plus one or more of the following:\n\n   * Hormonal contraceptives (e.g., birth control pills, skin patches, vaginal rings, and the Depo-Provera shot)\n   * Intrauterine device (IUD)\n   * Male or female condoms with spermicide\n   * Diaphragm with spermicide\n   * Permanent tubal occlusive birth control system\n7. Sufficient area of burn wound for realSKIN and comparator autograft placement to not be located on face or hands or having a target graft site centered on high-impact areas such as joints, weight-bearing areas (e.g. soles of feet), or the inguinal region, per Investigator's judgment\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Documented history of infection with human immunodeficiency virus (HIV) or other condition(s) that in the opinion of the Investigator may compromise patient safety or study objectives\n3. Immunosuppressive medication regimens e.g. antineoplastics, high dose steroids (\\>10 mg prednisone\u002Fday), TNF alpha inhibitors, calcineurin inhibitors (cyclosporine, tacrolimus), anti- proliferative agents, and other immunomodulators\n4. Active malignancy, including those requiring surgery, chemotherapy, and\u002For radiation in the past 5 years; non-metastatic basal or squamous cell carcinoma of the skin and cervical carcinoma in situ are allowed\n5. Use of any experimental or investigational drugs within 30 days prior to placement of realSKIN\n6. Previously received a porcine or other xenogeneic tissue product, including but not limited to: glutaraldehyde fixed porcine or bovine bioprosthetic heart valve replacements and glutaraldehyde fixed porcine dermal matrix (e.g., EZ Derm)\n7. Patients with advanced or unstable\u002Funcontrolled comorbid conditions, such as advanced renal disease, diabetes mellitus and liver disease\n8. Patients with HbA1c ≥ 10.0%; specimen must be obtained for screening purposes if current (within past 3 months) value is not available\n9. Patients with a history of chronic end stage renal disease defined as MDRD CrCL \\\u003C 15mL\u002Fmin or receiving chronic dialysis\n10. Patients with a history of chronic liver disease or cirrhosis (Child-Pugh Score C); evidence of acute or chronic hepatitis B infection based on documented HBV serology testing\n11. Known documented history of Hepatitis B, Hepatitis C, Treponema pallidum, Cytomegalovirus, herpes or varicella zoster; note: Successfully treated hepatitis C patients without evidence of end stage liver disease is allowed; if HCV antibody reactive, then HCV RNA must be undetectable\n12. Recent (within 3 months prior to study enrollment) MI, unstable angina leading to hospitalization, uncontrolled, CABG, PCI, carotid surgery or stenting, cerebrovascular accident, transient ischemic attack, endovascular procedure, or surgical intervention for peripheral vascular disease or plans to undergo a major surgical or interventional procedure (e.g., PCI, CABG, carotid or peripheral revascularization)\n13. Presence of venous or arterial vascular disorder directly affecting the area of burn wound\n14. Pre-existing haemolytic anemia\n15. Chronic malnourishment as determined by Investigator\n16. Inhalation injury as determined by bronchoscopic exam if available, or diagnosis at the time of screening\n17. Systemic anticoagulation at the time of treatment or INR \\> 2\n18. Documented evidence of wound infection at Screening\n19. Evidence of sepsis at Screening",{"count":513,"type":21},50,[83],"To evaluate the safety and efficacy of realSKIN® to provide complete wound closure of mixed-depth, full-thickness burn wounds as an alternative treatment to autografting.",[517,518,519,520,28],"Burns Degree Third","Burn (Disorder)","Burn Degree Second","Thermal Burn",[522,523,524,525,526,527,528,529,530,531,532,533],"Full-thickness Burn","Complete Wound Closure","Durable Wound Closure","Autograft Alternative","3rd Degree Burn","Mixed-Depth Burn","Partial-thickness Burn","4th Degree Burn","Xenotransplant","Xenograft","Skin Xenotransplant","realSKIN","2025-04-01",{"date":536,"type":36},"2025-04-02",{"date":538,"type":36},"2024-05-09",{"date":540,"type":21},"2026-01",{"name":542,"class":43},"XenoTherapeutics, Inc.",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":262,"acronym":263,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":22,"phases":550,"briefSummary":268,"conditions":551,"keywords":553,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":561},"100570427","phase-3-tissue-repair-gel-in-venous-leg-ulcers-in-auus-100570427","NCT06707103","Tissue Repair Gel in Venous Leg Ulcers in AU\u002FUS","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* History of cancer in the preceding 5 years (except as noted in the protocol).\n* Participants considered nutritionally deficient.",{"count":266,"type":21},[83],[114,270,271,272,28,552,274,275],"Wound",[277,278,279,280,281],"2025-03-27",{"date":536,"type":36},{"date":557,"type":21},"2025-04",{"date":559,"type":21},"2027-02",{"name":279,"class":290},12,{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":569,"enrollmentInfo":570,"targetDuration":4,"studyType":572,"phases":4,"briefSummary":573,"conditions":574,"keywords":577,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":4},"100585092","nursing-students-education-virtual-reality-wound-care-100585092","NCT06897865","Nursing Students Education Virtual Reality Wound Care","The Effect of Pressure Sore Preventıon Traınıng Wıth Vırtual Realıty on Satisfaction and Self-Confıdence Perceptıon in Nursıng Students","İnclusion Criteria\n\n* Nursing Students,\n* 2nd year nursing student\n\nExclusion Criteria\n\n* not a nursing student\n* 1st, 3rd or 4th year nursing student","45 Years",{"count":571,"type":21},70,"OBSERVATIONAL","This study is a randomized controlled trial aiming to determine the effect of pressure sore prevention education given to nursing students at a foundation university through virtual reality on student satisfaction, self-confidence perception and knowledge retention. The study will investigate whether virtual reality training affects student satisfaction and self-directed learning skills, differences between pre-test and post-test scores, and retention of the training. 66 nursing students will be included in the study, the experimental group will be trained with VR goggles and the control group will be provided with written material. The data obtained during the data collection process will be analyzed with the SPSS V23.0 program, descriptive statistics and appropriate parametric or nonparametric tests will be used. The measurement tools to be used include the 20-question \"Knowledge Assessment Form for Pressure Ulcer Prevention\" developed by Jeffries \\& Rizzolo and the \"Student Satisfaction and Self-Confidence in Learning Scale\". Ethics committee approval, relevant permissions and participant consent will be obtained for the study and the data obtained will be stored for 5 years and then destroyed. The literature review reveals the widespread use of virtual reality in education, healthcare and other fields and the critical role of pressure sore prevention in reducing healthcare costs and improving the quality of patient care.",[575,28,576],"Nurse's Role","Prevention",[578,579,580],"nursing","virtual reality","wound care","2025-03-20",{"date":554,"type":36},{"date":584,"type":21},"2025-03-21",{"date":586,"type":21},"2025-07-01",{"name":588,"class":43},"Ankara Medipol University",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":596,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":22,"phases":599,"briefSummary":600,"conditions":601,"keywords":605,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":614,"locationsCount":71},"100562279","phase-3-effects-of-topical-insulin-on-corneal-epithelium-healing-after-corneal-crosslinking-in-patients-with-keratoconus-100562279","NCT06601101","Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus","Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients with a diagnosis of keratoconus, indicated for corneal crosslinking\n\nExclusion Criteria:\n\n* Diabetes Mellitus\n* Severe dry eye\n* Limbal Stem Cell Deficiency\n* Glaucoma\n* Insulin or methylcellulose allergy","14 Years",{"count":598,"type":21},36,[83],"The cornea plays a fundamental role in vision, being a complex tissue essential for ocular health. In ophthalmological practice, there are situations such as corneal crosslinking, where damage to the corneal epithelium occurs. Crosslinking is a surgical procedure aimed at strengthening collagen bonds in the corneal stroma to prevent the progression of keratoconus, through the application of topical riboflavin followed by ultraviolet (UV-A) radiation. To enhance the effectiveness of riboflavin and UV-A radiation, the corneal epithelium needs to be removed, which can cause postoperative pain and discomfort, as well as increase the risk of complications such as infections, scarring, corneal opacities, perforations, and recurrent epithelial erosions. Several growth factors play a role in epithelial healing, and the discovery of insulin in the tear film and the presence of insulin and Insulin-Like Growth Factor (IGF-1) receptors in the cornea has raised the hypothesis that insulin may modulate the cornea's wound healing response. Since then, topical insulin has been used for various ocular pathologies, including dry eye disease, persistent epithelial defects, and neurotrophic ulcers. Based on this knowledge, studies have been developed, and promising results regarding the use of insulin in corneal healing have been reported, providing a scientific foundation for the realization of this project. The objective of this study is to evaluate the effect of insulin eye drops at a concentration of 50 IU\u002Fml on epithelial healing in non-diabetic patients undergoing epithelial debridement for corneal crosslinking. To this end, a randomized, double-masked clinical trial will be conducted with two groups, one being the control group, in which researchers will compare the epithelial healing rate in mm²\u002Fh between the insulin group and the placebo group, as the primary outcome. Patients diagnosed with keratoconus and with an indication for the crosslinking procedure, will be invited to participate. As a result of the study, it is expected to assess and quantify the impact of topical insulin on epithelial defect closure in patients undergoing crosslinking, compared to placebo. Topical insulin may contribute to early epithelial defect closure, control of inflammation, and prevention of complications that could significantly impact visual quality.",[602,603,604,28],"Keratoconus","Cornea Disease","Eye Diseases",[606,607],"Topical Insulin","Crosslinking","2025-01-10",{"date":610,"type":36},"2025-01-14",{"date":612,"type":36},"2024-08-01",{"date":124,"type":21},{"name":615,"class":43},"University of Campinas, Brazil",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":17,"minAge":623,"maxAge":4,"enrollmentInfo":624,"targetDuration":4,"studyType":22,"phases":625,"briefSummary":626,"conditions":627,"keywords":629,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":71},"100368594","oasis-donor-site-wounds-post-market-study-100368594","NCT04079348","Oasis Donor Site Wounds Post-Market Study","Feasibility Study to Compare OASIS Extracellular Matrix to Standard Wound Care for Treatment of Donor Site Wounds","Inclusion Criteria:\n\n1. Has a split thickness skin graft (STSG) donor site wound no greater than 14 x 20 cm in size requiring placement of a covering material.\n2. Has at least 24 hours to consent to study participation.\n\nExclusion Criteria:\n\n1. Age \\\u003C 16 years\n2. Patients who, in the opinion of the investigator, have co-morbidities that impair wound healing, such as:\n\n   1. Chronic inflammatory skin condition\n   2. Chronic liver failure\n   3. Chronic renal failure\n   4. Blood-borne viruses (Hep B, Hep C, HIV)\n   5. Peripheral vascular disease\n   6. Clinically significant anaemia\n   7. Uncontrolled diabetes\n3. Need for use of the same harvest site (re-cropping)\n4. History of radiation therapy to proposed donor site\n5. Chronic use of medications known to impair wound healing\n6. Chronic use of opioids or neuropathic pain agents\n7. Suspected cellulitis, osteomyelitis or septicaemia\n8. Patients undergoing haemodialysis\n9. Patients requiring spinal\u002Fregional block\n10. Patients on current anti-coagulant therapy\n11. Unable or unwilling to provide informed consent\n12. Unable or unwilling to comply with the study follow-up schedule, and procedures\n13. Simultaneously participating in another investigational drug or device study (patient must have completed the follow-up phase for the primary endpoint of any previous study at least 30 days prior to enrolment in this study)\n14. Allergy or hypersensitivity to materials that are porcine-based\n15. Cultural or religious objection to the use of pig or porcine products\n16. Known intolerance\u002Fallergy to standard wound care products\n17. Presence of a local infection at the donor site and\u002For systemic infection","16 Years",{"count":395,"type":21},[24],"The purpose of this study is to demonstrate the safety and performance of Oasis extracellular matrix (ECM) when used as a treatment for donor site wounds in the United Kingdom. Oasis ECM is commercially available for the treatment of partial and full-thickness skin wounds, including chronic wounds, wounds from trauma, and wounds that occur during surgery, such as donor site wounds. The ability of the Oasis ECM to promote the healing of donor site wounds will be evaluated in this study.\n\nAbout 40 patients (20 in each arm) over 16 years old will be involved in this study at one center in the United Kingdom.",[628,552,428,28],"Surgical Wound",[630],"Donor Site Wound","2024-12-12",{"date":633,"type":36},"2024-12-17",{"date":635,"type":36},"2020-11-01",{"date":637,"type":21},"2025-12",{"name":639,"class":290},"Cook Biotech Incorporated",{"id":641,"slug":642,"hasResults":12,"nctId":643,"briefTitle":644,"officialTitle":645,"acronym":4,"eligibilityCriteria":646,"healthyVolunteers":423,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":647,"targetDuration":4,"studyType":22,"phases":648,"briefSummary":649,"conditions":650,"keywords":653,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":44},"100557636","comparison-of-palatal-wound-healing-in-diabetic-and-non-diabetic-patients-100557636","NCT06540690","Comparison of Palatal Wound Healing in Diabetic and Non-diabetic Patients","Comparison of Palatal Wound Healing in Diabetic and Non-diabetic Patients: Controlled Clinical Trial and in Vitro Study","Inclusion Criteria:\n\n* Patients with at least 18 years, systemically healthy, with good oral hygiene, assessed by plaque index and gingival index less than 25% (Ainamo, Bay, 1975);\n* Patients with no morphological or pathological conditions on the palatine donor area;\n* Patients who present indication for extraction and ridge preservation;\n* The tooth included in the study, as well as, the adjacent teeth do not present loss of periodontal insertion;\n* Patients who agreed to and sign the formal consent to participate in the study after receiving an explanation of risks and benefits from an individual who was not a member of the present study (Resolution no. 118 - May, 2012, and Ethics and Code of Professional Conduct in Dentistry - 118\u002F12).\n* Patients diagnosed with type 2 diabetes for more than 5 years who are using oral hypoglycemic agents or insulin supplementation, with HbA1c levels ranging from ≥ 6.1% to 8.5%.\n* Non-diabetic patients with HbA1c levels below 6.1%.\n\nExclusion Criteria:\n\n* Patients with systemic problems (cardiovascular, blood dyscrasias, immunodeficiency, and diabetes, among others) that will contraindicate the surgical procedure;\n* Patients taking medications known to interfere with the wound healing process or that contraindicate the surgical procedure;\n* Smokers patients;\n* Pregnant or lactating patients;\n* Patients who had had periodontal surgery on the study area;\n* Patients who presents opportunistic oral lesions, mainly colonized the palate region;\n* Use of dental prosthesis with palatal cover;\n* Thin palatal mucosa (\\~2.0mm).",{"count":513,"type":21},[24],"This study aims to characterize and compare the closure of open wounds in the palatal mucosa of diabetic and non-diabetic patients, evaluate clinical, patient-centered and immunological parameters as well as wound microbiome composition.",[651,28,652],"Palate; Wound","Diabetes",[654,655,656,652],"Periodontology","Wound healing","Controlled Clinical Trial","2024-08-02",{"date":659,"type":36},"2024-08-06",{"date":661,"type":36},"2023-08-01",{"date":663,"type":21},"2027-01-06",{"name":665,"class":43},"Universidade Estadual Paulista Júlio de Mesquita Filho"]